U-CH1 (ATCC® CRL-3217)

Organism: Homo sapiens, human  /  Tissue: sacral bone  /  Disease: tumor, chordoma

Organism Homo sapiens, human
Tissue sacral bone
Product Format frozen
Morphology mesenchymal like, with variable vacuoles
Culture Properties adherent
Biosafety Level 1
Disease tumor, chordoma
Age 56 years
Gender male
Ethnicity Caucasian
Applications
Use as a model of chordoma which is a rare slow-growing tumor

The Chordoma Foundation can offer financial assistance for the purchase of this cell line. Please contact cells@chordoma.org for more information.
Shipping Information frozen
Storage Conditions liquid nitrogen vapor phase
Images Cell micrograph of ATCC CRL-3217 ( U-CH1 human chordoma)
Derivation This cell line was established from a local recurrence of a sacrococcygeal after radiotherapy 4 years after initial surgery.
Clinical Data 56 years
male
Caucasian
Genes Expressed overexpression of transcription factor T (brachyury)
Comments U-CH1 is the first human chordoma cell line. It exhibits chordoma-like characteristics and has molecular, genetic, and morphological features typical of chordoma. This cell line was established from a local recurrence of a sacrococcygeal chordoma after radiotherapy 4 years after initial surgery. Chordoma is a rare slow-growing tumor type, and U-CH1 is a relatively slow-growing cell line. U-CH1 has a heterogeneous morphology consisting of physaliferous cells with mcinous intercellular substance, which represent typical chordoma features. The cells overexpress the transcription factor T (Brachyury) that is the most specific marker for chordoma. This cell line was accessioned with the support of the Chordoma Foundation, a non-profit organization working to improve the lives of chordoma patients by accelerating research to develop effective treatments for the chordoma disease.
Complete Growth Medium IMDM: RPMI-1640 (4:1) +10% FBS
Subculturing

Coating description: Dilute rat tail type I collagen (BD Biosciences, Catalog No. 354236) to 50ug/ml. Add 7.5 ml coating buffer to flask and incubate at room temperature for one hour. Carefully aspirate remaining solution. Rinse flask 2 times to remove acid, using 1x DPBS. Coated flasks may be used immediately or stored at 2-8°C up to one week under sterile conditions.

Volumes used in this subculture protocol are for a 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 5.0ml Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS) or 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
  3. Add 5.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 5.0 ml of complete growth medium and aspirate cells by gently pipetting.
  5. Transfer cell suspension to a centrifuge tube and spin at approximately 125 x g for 5 to 10 minutes. Discard supernatant.
  6. Resuspend the cell pellet in 10 ml fresh growth medium.
  7. Add appropriate aliquots of the cell suspension to new coated culture vessels.
  8. Incubate cultures at 37°C.
Cryopreservation Freeze medium: 70% complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO
Culture Conditions Temperature: 37oC
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile

                TH01: 7
                D5S818: 11, 12           
                D13S317: 11, 13
                D7S820: 9, 12
                D16S539: 12, 13
                CSF1PO: 10, 11
                Amelogenin: X Y
                vWA: 17
                TPOX: 8, 11

Passage Number 30
Name of Depositor Silke Bruderlein, Peter Moller
Year of Origin August 17, 1998
References

Scheil S, et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32(3): 203-211, 2001. PubMed: 11579460

Bruderlein S, et al. Molecular characterization of putative chordoma cell lines. Sarcoma 2010: 630129. Epub 2010 Dec 30. PubMed: 21253487

Presneau N, et al. Role of the transcription factor T (brechyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J. Pathol. 2239(3): 327-335, 2011. PubMed: 21171078

Liu X, et al. Establishment and Characterization of a Novel Chordoma Cell Line: CH22. J. Orthip Res. 30 (10): 1666-1673, 2010. PubMed: 22504929

Basic Documentation
Other Documentation
References

Scheil S, et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32(3): 203-211, 2001. PubMed: 11579460

Bruderlein S, et al. Molecular characterization of putative chordoma cell lines. Sarcoma 2010: 630129. Epub 2010 Dec 30. PubMed: 21253487

Presneau N, et al. Role of the transcription factor T (brechyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J. Pathol. 2239(3): 327-335, 2011. PubMed: 21171078

Liu X, et al. Establishment and Characterization of a Novel Chordoma Cell Line: CH22. J. Orthip Res. 30 (10): 1666-1673, 2010. PubMed: 22504929